Elite Journal of Immunology. Volume 2 issue 2(2024), Pp. 15-28
https://epjournals.com/journals/EJI

Harnessing B Cell Responses for Personalized Approaches in HIV Management

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda. emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug 0000-0002-4538-0161

Abstract

This comprehensive review explores the forefront of HIV management through the lens of personalized medicine, with a specific focus on harnessing B cell responses. The dynamic interplay between the virus and the adaptive immune system, particularly B cells, forms the crux of this examination. Keywords: HIV, B cells, Personalized Medicine, Adaptive Immunity, Antibody Responses, Vaccine Development. Antibody responses, pivotal components of B cell-mediated immunity, are a central focus in HIV research. This review delves into the diversity and specificity of antibody responses, exploring their potential in therapeutic interventions and vaccine development. The quest for broadly neutralizing antibodies takes center stage as we navigate the implications of B cell dynamics on personalized medicine. Heterogeneity in B cell responses among individuals with HIV necessitates a nuanced approach to personalized medicine. Factors such as viral diversity, host genetics, and the timing of antiretroviral therapy initiation contribute to this heterogeneity, providing insights into tailoring interventions based on individual immune profiles. The establishment and maintenance of B cell memory emerge as crucial components in long-term immune control. This review explores the mechanisms underlying the persistence of memory B cells in HIV-infected individuals, presenting opportunities for personalized strategies aimed at achieving sustained viral suppression.

Keywords: *HIV, B cells, Personalized Medicine, Adaptive Immunity, Antibody Responses, Vaccine Development.*

Introduction

Citation: Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management**.** Elite Journal of Immunology, 2024; 2(2): 15-28

The management of Human Immunodeficiency Virus (HIV) infection has undergone transformative shifts over the years, driven by advancements in our understanding of the virus and the immune responses it elicits. In this era of precision medicine, there is a growing recognition of the need for personalized approaches to HIV management. Among the various components of the immune system, B cells, with their ability to produce antibodies and shape adaptive immunity, have emerged as key players in the battle against HIV [1-11]. HIV, a complex retrovirus, has proven to be a formidable adversary, evading conventional immune responses and persisting in the host for extended periods. While antiretroviral therapy (ART) has revolutionized HIV care, achieving a cure remains elusive [12-17]. This backdrop underscores the urgency of novel approaches that capitalize on the intricacies of the immune system, with B cells taking center stage in this narrative.

The concept of personalized medicine, tailoring interventions to the unique characteristics of each individual, has gained prominence in the field of HIV research [18]. The heterogeneity in host-virus interactions and immune responses necessitates a departure from one-size-fits-all approaches. B cells, with their diverse repertoire and the ability to generate specific antibodies, offer a promising avenue for such tailored interventions. This paper aims to dissect the multifaceted role of B cells in the context of HIV infection and explore the potential for harnessing B cell responses in personalized HIV management. From the early stages of infection to the establishment of memory, B cells contribute significantly to both protective and potentially pathogenic responses.

B Cell Dynamics in HIV Infection

Upon exposure to HIV, B cells undergo rapid activation characterized by the recognition of viral antigens. The diversity of the HIV envelope glycoprotein presents a formidable challenge and an opportunity for B cells to generate a broad spectrum of antibodies. This early phase sets the foundation for the subsequent immune response, marking the initial encounter between the adaptive immune system and the virus [18-28]. Activated B cells undergo class switching, a process that determines the type of antibodies produced. In the context of HIV, class switching is crucial for generating antibodies with diverse effector functions. The production of immunoglobulin G (IgG) antibodies, particularly those with potent neutralizing capabilities, plays a pivotal role in limiting viral spread and shaping the course of infection [29-38].

Germinal centers, specialized microenvironments within lymphoid tissues, serve as epicenters for B cell maturation. Here, B cells undergo affinity maturation and selection processes, fine-tuning their antibody specificity and enhancing their ability to recognize and neutralize HIV. Understanding the dynamics of germinal center reactions provides insights into the evolution of B cell responses over the course of infection. Chronic HIV infection is associated with B cell exhaustion—a state of functional impairment marked by decreased antibody production and altered B cell phenotypes. Factors contributing to B cell exhaustion include prolonged exposure to viral antigens, dysregulation of immune checkpoints, and the influence of regulatory T cells. Unraveling the mechanisms of B cell exhaustion is crucial for mitigating its impact on long-term

immune control [39-48]. In addition to effector B cells, a subset known as regulatory B cells (Bregs) exerts immunomodulatory functions. Bregs play a role in maintaining immune homeostasis and regulating inflammatory responses. The delicate balance between effector and regulatory B cell subsets is disrupted in HIV infection, influencing the overall immune landscape. The complex interplay between B cells and HIV has implications for viral persistence [49]. While neutralizing antibodies contribute to the containment of viral replication, the virus employs various evasion strategies, such as the generation of viral variants and resistance to antibody-mediated neutralization. Understanding these strategies is imperative for developing interventions aimed at achieving sustained viral control.

Role of Antibody Responses

Neutralizing antibodies (NAbs) stand at the forefront of defense against HIV by directly interfering with the virus's ability to infect host cells [50]. The quest for broadly neutralizing antibodies (bNAbs), capable of neutralizing a broad spectrum of HIV variants, has been a focal point of research. Antibodies, even in the absence of potent neutralization, can contribute to the control of HIV through antibody-dependent cellular cytotoxicity (ADCC). By recruiting effector cells such as natural killer (NK) cells, antibodies facilitate the destruction of HIV-infected cells [51]. The balance between protective ADCC and potential enhancement of infection underscores the complexities of harnessing this mechanism for therapeutic purposes. Antibody-dependent cellular phagocytosis (ADCP) involves the engulfment of virus-bound antibodies by phagocytic cells. This process contributes to the clearance of antibody-coated virus particles, limiting viral dissemination. Investigating the nuances of ADCP provides insights into additional mechanisms through which antibodies influence HIV pathogenesis. Beyond neutralization, non-neutralizing antibodies play roles in modulating the immune response. Their engagement of Fc receptors on various immune cells can trigger downstream effector functions, influencing viral control and shaping the overall immune landscape. Understanding the balance between neutralizing and non-neutralizing antibodies is crucial for optimizing therapeutic interventions.

The maturation of antibody responses involves processes such as affinity maturation, where B cells undergo iterative rounds of mutation and selection to enhance the specificity and avidity of their antibodies. The trajectory of affinity maturation in response to HIV provides insights into the adaptability of the humoral immune response and its potential for shaping long-term immunity [52-59]. The dynamic nature of HIV, characterized by rapid mutation and evolution, poses challenges to the durability of antibody responses. The virus employs escape mechanisms to evade neutralization by antibodies, contributing to the persistence of viral reservoirs. Unraveling the intricate dance between viral evolution and antibody responses is vital for devising strategies to overcome viral escape [60-67].

Heterogeneity in B Cell Responses

The immune landscape during HIV infection is marked by a remarkable diversity in B cell responses among individuals. Heterogeneity in the dynamics of B cell-mediated immunity arises

from a myriad of factors, including viral diversity, host genetics, and the timing of antiretroviral therapy initiation. This section delves into the intricate tapestry of B cell responses, exploring the variations observed among individuals with HIV and their implications for personalized approaches to HIV management [68-73]. The genetic diversity of HIV presents a formidable challenge for B cells attempting to recognize and neutralize the virus. The antigenic variability, particularly in the envelope glycoprotein, influences the breadth and specificity of B cell responses. Variations in viral quasispecies among individuals contribute to the diverse array of antibodies generated in response to infection.

The genetic makeup of the host plays a pivotal role in shaping B cell responses to HIV [74]. Polymorphisms in genes encoding components of the immune system, including HLA molecules, influence the specificity and efficacy of B cell responses. Understanding the interplay between host genetics and B cell immunity provides insights into the heterogeneity observed in immune outcomes.

The timing of antiretroviral therapy (ART) initiation has profound effects on B cell responses. Early initiation of ART may preserve B cell function, limit immune exhaustion, and enhance the likelihood of developing broadly neutralizing antibodies (bNAbs). In contrast, delayed initiation may contribute to persistent B cell dysfunction and altered antibody profiles. Exploring the impact of ART timing on B cell dynamics contributes to understanding the heterogeneity in long-term immune outcomes [75-78].

Chronic immune activation, a hallmark of HIV infection, contributes to B cell exhaustion—a state of functional impairment characterized by decreased antibody production and altered B cell phenotypes [79]. The degree of immune activation varies among individuals and influences the extent of B cell exhaustion. Unraveling the mechanisms of B cell exhaustion is crucial for tailoring interventions to mitigate its impact.

Heterogeneity in B cell responses extends to the variable efficacy of therapeutic interventions. Some individuals exhibit robust responses to antiretroviral therapy, experiencing immune reconstitution and restoration of B cell function. In contrast, others may face persistent immune challenges, necessitating alternative or intensified therapeutic strategies. Tailoring interventions based on individual responses is paramount for optimizing treatment outcomes. B cell responses evolve over the course of HIV infection, influenced by factors such as viral dynamics, immune modulation, and therapeutic interventions [80]. The intricate heterogeneity in B cell responses among individuals with HIV underscores the need for personalized approaches to HIV management. Tailoring interventions based on the unique characteristics of an individual's immune profile, including B cell dynamics, has the potential to optimize treatment outcomes and enhance long-term immune control.

B Cell Memory and Long-Term Control

The establishment and maintenance of B cell memory play pivotal roles in the long-term immune control of HIV. B cell memory, a testament to the adaptive capabilities of the immune system, is integral for sustained protection against viral challenges. This section explores the nuances of B cell memory in the context of HIV infection, shedding light on its establishment, maintenance, and implications for long-term control of the virus. Following exposure to HIV or vaccination, a subset of B cells differentiates into long-lived memory B cells [81]. These cells harbor the immunological memory of prior encounters with the virus, poised to mount a rapid and robust response upon re-exposure. Understanding the factors influencing the generation of durable memory B cells is crucial for designing effective vaccines and therapeutic strategies.

Memory B cells contribute to the persistence of antibody responses over time. This enduring humoral immunity, characterized by the presence of specific antibodies in circulation, serves as a critical line of defense against HIV. Exploring the dynamics of antibody persistence provides insights into the longevity of B cell memory and its impact on long-term viral control. Germinal centers, specialized microenvironments within lymphoid tissues, play a central role in the maintenance of B cell memory. These structures facilitate ongoing processes of affinity maturation and selection, contributing to the generation of high-affinity, long-lived memory B cells. The intricate interplay within germinal centers shapes the durability and specificity of B cell memory responses [81]. Memory B cells exhibit the remarkable ability to undergo rapid recall responses upon re-exposure to the virus. This rapid mobilization enables the immune system to mount a swifter and more effective defense during secondary encounters with HIV. Understanding the mechanisms underlying the recall responses of memory B cells is essential for elucidating their contributions to long-term immune control.

The durability of memory B cell responses in the context of chronic HIV infection varies among individuals. Factors such as the degree of immune activation, the persistence of viral reservoirs, and the effectiveness of antiretroviral therapy influence the longevity of memory B cell responses. Investigating the determinants of durable B cell memory provides insights into optimizing long-term immune control.

Strategies to enhance B cell memory in the context of HIV management are actively pursued. Vaccine development endeavors aim to elicit robust and durable memory B cell responses. Additionally, interventions targeting the modulation of immune checkpoints and the mitigation of B cell exhaustion may contribute to the enhancement of memory B cell function [81]. The establishment and maintenance of B cell memory have profound implications for achieving long-term viral suppression. Robust memory B cell responses contribute to the prevention of viral escape and the sustained control of viral replication. Tailoring therapeutic interventions to enhance B cell memory may be pivotal in optimizing the long-term outcomes of individuals with HIV.

Therapeutic Implications and Future Directions

As our understanding of B cell dynamics in HIV continues to deepen, the therapeutic implications of harnessing these responses become increasingly apparent. This section explores current and

potential therapeutic interventions that leverage B cell responses in the management of HIV. Additionally, it outlines future directions for research, emphasizing the need for continued exploration to optimize personalized approaches and enhance the effectiveness of B cell-centric strategies. Monoclonal antibodies (mAbs) targeting specific epitopes on HIV have emerged as promising therapeutic agents. These mAbs, whether derived from natural bNAbs or engineered to mimic their properties, hold potential for neutralizing the virus and modulating immune responses. Ongoing clinical trials are evaluating the safety and efficacy of mAbs as therapeutic options, offering a glimpse into the future landscape of B cell-centric interventions.

The quest for an effective HIV vaccine has been ongoing for decades, with B cell responses playing a central role in vaccine-induced immunity. Strategies aiming to elicit broadly neutralizing antibodies and durable memory B cell responses are at the forefront of vaccine development. Advances in understanding the complexities of B cell dynamics provide critical insights for refining vaccine candidates and enhancing their immunogenicity. The modulation of immune checkpoints has emerged as a strategy to alleviate B cell exhaustion and enhance immune responses in chronic HIV infection. Therapies targeting checkpoint molecules, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have shown promise in preclinical studies. Clinical trials exploring the safety and efficacy of immune checkpoint inhibitors in HIV management are underway, paving the way for potential interventions to reinvigorate B cell responses.

Optimizing antiretroviral therapy (ART) strategies based on individual B cell dynamics holds potential for improving treatment outcomes. Early initiation of ART, guided by an understanding of its impact on B cell exhaustion and immune reconstitution, may contribute to preserving B cell function and promoting long-term immune control. Tailoring ART regimens to individual immune profiles is a step towards personalized HIV care. Advancements in gene therapies offer novel avenues for modulating B cell responses. Genetic engineering techniques, such as CRISPR-Cas9, hold potential for precisely modifying B cells to enhance their antiviral properties. Exploring the safety and feasibility of gene therapies for manipulating B cell responses in HIV is an evolving area of research with transformative implications for personalized medicine.

B cell responses are intricately linked to the persistence of viral reservoirs in HIV. Therapeutic strategies aimed at disrupting or eliminating these reservoirs may enhance the effectiveness of B cell-centric interventions. Innovative approaches, including latency-reversing agents and immunotherapies targeting viral reservoirs, are under investigation for their potential to complement B cell-focused therapeutic strategies. The dynamic landscape of B cell responses in HIV necessitates ongoing research to address critical gaps and refine therapeutic approaches. Future directions include further exploration of the interplay between viral evolution and B cell responses, the impact of comorbidities on B cell function, and the development of innovative technologies for precision targeting of B cells. Collaborative efforts between researchers, clinicians, and individuals with HIV will be crucial for advancing the field.

Conclusion

Citation: Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management**.** Elite Journal of Immunology, 2024; 2(2): 15-28

The journey through the intricate landscape of B cell responses in HIV has illuminated a path towards innovative and personalized strategies in the management of this complex virus. B cells, with their dynamic roles in antibody production, memory formation, and immune regulation, have emerged as central players in the ongoing battle against HIV. As we conclude this exploration, it is evident that leveraging B cell responses holds profound implications for the future of HIV care. The development of monoclonal antibodies, either mimicking the properties of natural broadly neutralizing antibodies or derived from them, represents a promising frontier. These antibodies showcase the potential to neutralize diverse viral strains, offering both therapeutic and preventive avenues. Simultaneously, ongoing efforts in vaccine development strive to elicit robust and durable memory B cell responses, providing a foundation for sustained immunity. Immune checkpoint modulation presents a novel approach to alleviate B cell exhaustion, reinvigorating immune responses in chronic HIV infection. As the field of gene therapies advances, precision engineering of B cells holds the potential to enhance their antiviral properties, paving the way for innovative interventions.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001

Citation: Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management**.** Elite Journal of Immunology, 2024; 2(2): 15-28

8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-9.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

Citation: Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management**.** Elite Journal of Immunology, 2024; 2(2): 15-28

18. Owolabi P, Adam Y, Adebiyi E. Personalizing medicine in Africa: current state, progress and challenges. Frontiers in Genetics. 2023;14.
19. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
20. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
21. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
22. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
23. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
24. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
25. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-34. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
26. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
27. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
28. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.

links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

29. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-42.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
30. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-34.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
31. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-4.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
32. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
33. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
34. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-83.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
35. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
36. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal

of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-11. http://research.sdpublishers.net/id/eprint/2819/.

37. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
38. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-8.
39. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
40. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
41. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
42. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
43. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-9.
44. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
45. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
46. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
47. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-10. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
48. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
49. Zhou Y, Zhang Y, Moorman JP, Yao ZQ, Jia ZS. Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. Immunology. 2014;143(3):319-30.
50. Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunologic Research. 2020; 68:325-39.
51. Mikulak J, Oriolo F, Zaghi E, Di Vito C, Mavilio D. Natural killer cells in HIV-1 infection and therapy. AIDS (London, England). 2017;31(17):2317.
52. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
53. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
54. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-9.
55. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/Ii1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
56. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-30.
57. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-9.
58. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.

Citation: Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management**.** Elite Journal of Immunology, 2024; 2(2): 15-28

59. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-1.
60. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-71.
61. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
62. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-8.
63. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-6.
64. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
65. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5.
66. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-9.
67. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
68. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
69. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
70. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
71. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm

shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
72. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
73. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
74. Mouquet H. Antibody B cell responses in HIV-1 infection. Trends in immunology. 2014;35(11):549-61.
75. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
76. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
77. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
78. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
79. Amu S, Ruffin N, Rethi B, Chiodi F. Impairment of B-cell functions during HIV-1 infection. Aids. 2013;27(15):2323-34.
80. Upasani V, Rodenhuis-Zybert I, Cantaert T. Antibody-independent functions of B cells during viral infections. PLoS pathogens. 2021;17(7): e1009708.
81. Palm AK, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Frontiers in immunology. 2019; 10:1787.